U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H15NO2S
Molecular Weight 273.3517
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MODAFINIL

SMILES

c1ccc(cc1)C(c2ccccc2)S(=O)CC(=N)O

InChI

InChIKey=YFGHCGITMMYXAQ-UHFFFAOYSA-N
InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)

HIDE SMILES / InChI

Molecular Formula C15H15NO2S
Molecular Weight 273.3517
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil_prntlbl.pdf

Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. Modafinil is not indicated for complaints of lack of energy or fatigue; but it appears to be very helpful for some patients. Also, it has been used in the treatment of hypersomnia, a disorder in which patients lack the capacity for meaningful sleep and may require ten or more hours per day. Recent studies have have found that modafinil may help recovering cocaine addicts fight their addiction. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. Modafinil is thought to have less potential for abuse than other stimulants due to the absence of any significant euphoric or pleasurable effects. It is possible that modafinil acts by a synergistic combination of mechanisms including direct inhibition of dopamine reuptake, indirect inhibition of noradrenalin reuptake in the VLPO and orexin activation. Modafinil has partial alpha 1B-adrenergic agonist effects by directly stimulating the receptors. Modafinil is indicated for the improvement of wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
51.7899999999999991 µM [IC50]
51.7899999999999991 µM [IC50]
13 µM [Ki]
4 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PROVIGIL

Approved Use

Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).

Launch Date

914371200000
Primary
PROVIGIL

Approved Use

Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).

Launch Date

914371200000
Primary
NUVIGIL

Approved Use

NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. In OSA, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of NUVIGIL in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient.

Launch Date

1181865600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.4 μg/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.5 μg/mL
250 mg 1 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10 μg/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
13.4 μg/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.8 μg/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 μg/mL
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.9 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.1 μg/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.4 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.2 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
4.1 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
105.9 μg × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
136.1 μg × h/mL
250 mg 1 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
150.4 μg × h/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
189.5 μg × h/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
23.4 μg × h/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
56.2 μg × h/mL
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
142.9 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
146 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
15.9 μg × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
40.6 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
43.8 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
75.9 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.8 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
150 mg 1 times / day steady, oral
Recommended
dose: 150 mg 1 times / day
route: oral
experiment_type: steady
dose_type: Recommended
co-adm with
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/29734973
    unhealthy, 21 years
    population: unhealthy
    age: 21 years
    sex: F
    food_status:
    n:
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/29734973
    Disc. AE: Stevens-Johnson syndrome...
    AEs leading to
    discontinuation/dose reduction:​
    Stevens-Johnson syndrome (1 patient)

    data_source:
    https://pubmed.ncbi.nlm.nih.gov/29734973
    400 mg single, oral
    Highest studied dose
    dose: 400 mg
    route: oral
    experiment_type: single
    dose_type: Highest studied dose
    co-adm with
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/19133704
      healthy, 21–40 years
      population: healthy
      age: 21–40 years
      sex: M
      food_status:
      n:
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/19133704
      400 mg 1 times / day steady, oral
      Highest studied dose
      dose: 400 mg 1 times / day
      route: oral
      experiment_type: steady
      dose_type: Highest studied dose
      co-adm with
        data_source:
        https://pubmed.ncbi.nlm.nih.gov/19133704
        healthy, 21–40 years
        population: healthy
        age: 21–40 years
        sex: M
        food_status:
        n:
        data_source:
        https://pubmed.ncbi.nlm.nih.gov/19133704
        Disc. AE: Adverse event...
        AEs leading to
        discontinuation/dose reduction:​
        Adverse event

        data_source:
        https://pubmed.ncbi.nlm.nih.gov/19133704
        150 mg 1 times / day steady, oral
        Recommended
        dose: 150 mg 1 times / day
        route: oral
        experiment_type: steady
        dose_type: Recommended
        co-adm with
          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
          unhealthy
          population: unhealthy
          age:
          sex:
          food_status:
          n:
          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
          Disc. AE: Headache...
          AEs leading to
          discontinuation/dose reduction:​
          Headache (1%)

          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
          150 mg 1 times / day steady, oral
          Recommended
          dose: 150 mg 1 times / day
          route: oral
          experiment_type: steady
          dose_type: Recommended
          co-adm with
            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
            unhealthy
            population: unhealthy
            age:
            sex:
            food_status:
            n:
            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
            Disc. AE: Rash, Angioneurotic edema...
            AEs leading to
            discontinuation/dose reduction:​
            Rash (2%)
            Angioneurotic edema (1%)
            Hyperhidrosis (1%)
            Rash papular (1%)

            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
            AEs

            AEs

            AESignificanceDosePopulation
            Angioneurotic edema 1%
            Disc. AE
            150 mg 1 times / day steady, oral
            Recommended
            dose: 150 mg 1 times / day
            route: oral
            experiment_type: steady
            dose_type: Recommended
            co-adm with
              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
              unhealthy
              Headache 1%
              Disc. AE
              150 mg 1 times / day steady, oral
              Recommended
              dose: 150 mg 1 times / day
              route: oral
              experiment_type: steady
              dose_type: Recommended
              co-adm with
                data_source:
                https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
                unhealthy
                population:
                age:
                sex:
                food_status:
                n:
                data_source:
                https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
                Hyperhidrosis 1%
                Disc. AE
                150 mg 1 times / day steady, oral
                Recommended
                dose: 150 mg 1 times / day
                route: oral
                experiment_type: steady
                dose_type: Recommended
                co-adm with
                  data_source:
                  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
                  unhealthy
                  Rash papular 1%
                  Disc. AE
                  150 mg 1 times / day steady, oral
                  Recommended
                  dose: 150 mg 1 times / day
                  route: oral
                  experiment_type: steady
                  dose_type: Recommended
                  co-adm with
                    data_source:
                    https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
                    unhealthy
                    Rash 2%
                    Disc. AE
                    150 mg 1 times / day steady, oral
                    Recommended
                    dose: 150 mg 1 times / day
                    route: oral
                    experiment_type: steady
                    dose_type: Recommended
                    co-adm with
                      data_source:
                      https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
                      unhealthy
                      Stevens-Johnson syndrome 1 pts%
                      Disc. AE
                      150 mg 1 times / day steady, oral
                      Recommended
                      dose: 150 mg 1 times / day
                      route: oral
                      experiment_type: steady
                      dose_type: Recommended
                      co-adm with
                        data_source:
                        https://pubmed.ncbi.nlm.nih.gov/29734973
                        unhealthy, 21 years
                        population:
                        age:
                        sex:
                        food_status:
                        n:
                        data_source:
                        https://pubmed.ncbi.nlm.nih.gov/29734973
                        Adverse event
                        Disc. AE
                        400 mg 1 times / day steady, oral
                        Highest studied dose
                        dose: 400 mg 1 times / day
                        route: oral
                        experiment_type: steady
                        dose_type: Highest studied dose
                        co-adm with
                          data_source:
                          https://pubmed.ncbi.nlm.nih.gov/19133704
                          healthy, 21–40 years
                          population:
                          age:
                          sex:
                          food_status:
                          n:
                          data_source:
                          https://pubmed.ncbi.nlm.nih.gov/19133704
                          PubMed

                          PubMed

                          TitleDatePubMed
                          Modafinil augmentation of mirtazapine in a failure-to-thrive geriatric inpatient.
                          2002
                          Benefits and risks of pharmacotherapy for narcolepsy.
                          2002
                          Effects of modafinil on heat thermoregulatory responses in humans at rest.
                          2002 Aug
                          Drugs under investigation for attention-deficit hyperactivity disorder.
                          2002 Aug
                          Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.
                          2002 Dec
                          Role of brain alpha 1B-adrenoceptors in modafinil-induced behavioral activity.
                          2002 Dec 15
                          Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy.
                          2002 Dec 24
                          Narcolepsy and psychopathology: is there an association?
                          2002 Jul
                          Comparison of the effects of modafinil and sleep deprivation on sleep and cortical EEG spectra in mice.
                          2002 Jul
                          Gateways to clinical trials.
                          2002 Jul-Aug
                          Attention deficit disorder in adults.
                          2002 Jun
                          Effect of modafinil on core temperature during sustained wakefulness and exercise in a warm environment.
                          2002 Nov
                          Modafinil for social phobia and amphetamine dependence.
                          2002 Nov
                          Stress-induced subsensitivity to modafinil and its prevention by corticosteroids.
                          2002 Nov
                          Circadian rhythm of rectal temperature during sleep deprivation with modafinil.
                          2002 Oct
                          Clinical applications of modafinil in stimulant abusers: low abuse potential.
                          2002 Summer
                          Temporal pattern of hippocampal high-frequency oscillations during sleep after stimulant-evoked waking.
                          2003
                          Narcolepsy in the older adult: epidemiology, diagnosis and management.
                          2003
                          Fatigue in multiple sclerosis: definition, pathophysiology and treatment.
                          2003
                          [Therapy of day time fatigue in patients with multiple sclerosis].
                          2003
                          Clinical pharmacokinetic profile of modafinil.
                          2003
                          Three case reports of modafinil use in treating sedation induced by antipsychotic medications.
                          2003 Apr
                          Non-stimulant treatment of attention-deficit/hyperactivity disorder.
                          2003 Apr
                          Modafinil affects mood, but not cognitive function, in healthy young volunteers.
                          2003 Apr
                          Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies.
                          2003 Apr
                          An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy.
                          2003 Apr
                          Modafinil in children with attention-deficit hyperactivity disorder.
                          2003 Aug
                          TetraTab--cognitive enhancement gone wrong.
                          2003 Aug
                          [Modafinil: pharmacology and therapeutic perspectives].
                          2003 Jan
                          By the way, doctor. What can you tell me about the new drug Provigil? I've read that it helps people stay awake without feeling jittery. For those of us who work a lot of overtime, it sounds like a dream come true.
                          2003 Jan
                          Pharmacogenomics in the treatment of narcolepsy.
                          2003 Jan
                          Cognitive enhancing effects of modafinil in healthy volunteers.
                          2003 Jan
                          Should a pharmaceutical be approved for the broad indication of excessive sleepiness?
                          2003 Jan 15
                          Con: modafinil has no role in management of sleep apnea.
                          2003 Jan 15
                          Pro: modafinil has a role in management of sleep apnea.
                          2003 Jan 15
                          Modafinil treatment of opioid-induced sedation.
                          2003 Jun
                          Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy.
                          2003 Jun
                          Modafinil--medical considerations for use in sustained operations.
                          2003 Jun
                          Modafinil for treatment of cognitive side effects of antiepileptic drugs in a patient with seizures and stroke.
                          2003 Jun
                          Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies.
                          2003 Jun
                          Cataplexy worsened by modafinil.
                          2003 Jun 15
                          Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.
                          2003 Mar
                          Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG.
                          2003 Mar
                          Modafinil maintains waking in the fruit fly drosophila melanogaster.
                          2003 Mar 15
                          Modafinil increases histamine release in the anterior hypothalamus of rats.
                          2003 Mar 20
                          The safety and efficacy of modafinil in multiple sclerosis-related fatigue.
                          2003 Oct
                          Narcolepsy drug could be approved for wider use.
                          2003 Oct 4
                          The quest for a smart pill.
                          2003 Sep
                          You'll lose sleep over this pill.
                          2003 Sep 29
                          Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy.
                          2003 Sep-Oct
                          Patents

                          Sample Use Guides

                          The recommended dosage of NUVIGIL (armodafinil) for each indication is as follows: obstructive sleep apnea or Narcolepsy: 150 mg to 250 mg once a day in the morning. Shift work disorder: 150 mg once a day, taken approximately one hour prior to start of the work shift.
                          Route of Administration: Oral
                          Substance Class Chemical
                          Created
                          by admin
                          on Fri Jun 25 20:32:21 UTC 2021
                          Edited
                          by admin
                          on Fri Jun 25 20:32:21 UTC 2021
                          Record UNII
                          R3UK8X3U3D
                          Record Status Validated (UNII)
                          Record Version
                          • Download
                          Name Type Language
                          MODAFINIL
                          EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
                          USAN   INN  
                          Official Name English
                          NSC-759110
                          Code English
                          CEP-1538
                          Code English
                          THN-102 COMPONENT MODAFINIL
                          Code English
                          CEP 1538
                          Code English
                          ACETAMIDE, 2-((DIPHENYLMETHYL)SULFINYL)-
                          Systematic Name English
                          MODAFINIL [MART.]
                          Common Name English
                          DEP-1538
                          Code English
                          CRL 40476
                          Code English
                          NSC-751178
                          Code English
                          MODAFINIL [USP MONOGRAPH]
                          Common Name English
                          (+/-)-MODAFINIL
                          Common Name English
                          CRL-40476
                          Code English
                          THN102 COMPONENT MODAFINIL
                          Code English
                          MODAFINIL [USAN]
                          Common Name English
                          2-((DIPHENYLMETHYL)SULFINYL)ACETAMIDE
                          Systematic Name English
                          CRC-40476
                          Code English
                          MODIODAL
                          Brand Name English
                          MODAFINIL [JAN]
                          Common Name English
                          MODAFINIL [INN]
                          Common Name English
                          MODAFINIL [WHO-DD]
                          Common Name English
                          MODAFINIL CIV
                          USP-RS  
                          Common Name English
                          MODAFINIL [EP MONOGRAPH]
                          Common Name English
                          MODAFINIL [HSDB]
                          Common Name English
                          MODAPHONIL
                          Brand Name English
                          PROVIGIL
                          Brand Name English
                          MODAFINIL [MI]
                          Common Name English
                          MODAFINIL CIV [USP-RS]
                          Common Name English
                          MODAFINIL [VANDF]
                          Common Name English
                          MODAFINIL [ORANGE BOOK]
                          Common Name English
                          Classification Tree Code System Code
                          NCI_THESAURUS C47795
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          NDF-RT N0000175651
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          FDA ORPHAN DRUG 73793
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          FDA ORPHAN DRUG 536716
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          NDF-RT N0000175729
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          DEA NO. 1680
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          WHO-ATC N06BA07
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          NDF-RT N0000175769
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          WHO-VATC QN06BA07
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          LIVERTOX 649
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          Code System Code Type Description
                          INN
                          6055
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          DRUG BANK
                          DB00745
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          MERCK INDEX
                          M7584
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY Merck Index
                          USP_CATALOG
                          1445404
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY USP-RS
                          LACTMED
                          Modafinil
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          CAS
                          112111-49-6
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          SUPERSEDED
                          MESH
                          C048833
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          HSDB
                          7585
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          PUBCHEM
                          4236
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          FDA UNII
                          R3UK8X3U3D
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          EPA CompTox
                          68693-11-8
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          NCI_THESAURUS
                          C26661
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          IUPHAR
                          7555
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          CAS
                          68693-11-8
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          DRUG CENTRAL
                          1826
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          ChEMBL
                          CHEMBL1373
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          RXCUI
                          30125
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY RxNorm
                          EVMPD
                          SUB09026MIG
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          WIKIPEDIA
                          MODAFINIL
                          Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                          PRIMARY
                          Related Record Type Details
                          ENANTIOMER -> RACEMATE
                          TARGET -> INHIBITOR
                          BINDER->LIGAND
                          BINDING
                          ENANTIOMER -> RACEMATE
                          Related Record Type Details
                          METABOLITE -> PARENT
                          MAJOR
                          PLASMA
                          METABOLITE -> PARENT
                          MAJOR
                          PLASMA; URINE
                          Related Record Type Details
                          IMPURITY -> PARENT
                          CHROMATOGRAPHIC PURITY (HPLC/UV)
                          EP
                          IMPURITY -> PARENT
                          CHROMATOGRAPHIC PURITY (HPLC/UV)
                          EP
                          Related Record Type Details
                          ACTIVE MOIETY
                          Name Property Type Amount Referenced Substance Defining Parameters References
                          Volume of Distribution PHARMACOKINETIC
                          Biological Half-life PHARMACOKINETIC